These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24453741)

  • 1. Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.
    Cook SD; Dhib-Jalbut S; Dowling P; Durelli L; Ford C; Giovannoni G; Halper J; Harris C; Herbert J; Li D; Lincoln JA; Lisak R; Lublin FD; Lucchinetti CF; Moore W; Naismith RT; Oehninger C; Simon J; Sormani MP
    Int J MS Care; 2012; 14(3):105-14. PubMed ID: 24453741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
    Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP
    Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis: Advocacy, Dissemination, and Implementation Strategies.
    Saslow L; Li DKB; Halper J; Banwell B; Barkhof F; Barlow L; Costello K; Damiri P; Dunn J; Giri S; Maes M; Morrow SA; Newsome SD; Oh J; Paul F; Quarterman P; Reich DS; Shewchuk JR; Shinohara RT; Van Hecke W; van de Ven K; Wallin MT; Wolinsky JS; Traboulsee A
    Int J MS Care; 2020; 22(5):226-232. PubMed ID: 33177959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
    Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
    Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium-enhancing or active T2 magnetic resonance imaging lesions in multiple sclerosis clinical trials?
    Bonzano L; Roccatagliata L; Mancardi GL; Sormani MP
    Mult Scler; 2009 Sep; 15(9):1043-7. PubMed ID: 19570818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Need for Screening, Assessment, and Treatment for Cognitive Dysfunction in Multiple Sclerosis: Results of a Multidisciplinary CMSC Consensus Conference, September 24, 2010.
    Foley FW; Benedict RH; Gromisch ES; Deluca J
    Int J MS Care; 2012; 14(2):58-64. PubMed ID: 24453735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of magnetic resonance techniques in understanding and managing multiple sclerosis.
    Miller DH; Grossman RI; Reingold SC; McFarland HF
    Brain; 1998 Jan; 121 ( Pt 1)():3-24. PubMed ID: 9549485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep gray matter changes in relapsing-remitting multiple sclerosis detected by multi-parametric, high-resolution magnetic resonance imaging (MRI).
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Eur Radiol; 2021 Feb; 31(2):706-715. PubMed ID: 32851443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term evolution of new multiple sclerosis lesions enhancing on standard and triple dose gadolinium-enhanced brain MRI scans.
    Rovaris M; Mastronardo G; Prandini F; Bastianello S; Comi G; Filippi M
    J Neurol Sci; 1999 Apr; 164(2):148-52. PubMed ID: 10402026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
    Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
    JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
    BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-management for people with multiple sclerosis: report from the first international consensus conference, november 15, 2010.
    Fraser R; Ehde D; Amtmann D; Verrall A; Johnson KL; Johnson E; Kraft GH
    Int J MS Care; 2013; 15(2):99-106. PubMed ID: 24453769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Magnetic resonance imaging in multiple sclerosis].
    Tourbah A; Berry I
    Pathol Biol (Paris); 2000 Mar; 48(2):151-61. PubMed ID: 10815291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of sagittal short T1 inversion recovery and T2-weighted FSE sequences for detection of multiple sclerosis spinal cord lesions.
    Nayak NB; Salah R; Huang JC; Hathout GM
    Acta Neurol Scand; 2014 Mar; 129(3):198-203. PubMed ID: 23980614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
    BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.
    Miller DH; Albert PS; Barkhof F; Francis G; Frank JA; Hodgkinson S; Lublin FD; Paty DW; Reingold SC; Simon J
    Ann Neurol; 1996 Jan; 39(1):6-16. PubMed ID: 8572668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
    Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M
    Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.